<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04104074</url>
  </required_header>
  <id_info>
    <org_study_id>19048-0-01</org_study_id>
    <nct_id>NCT04104074</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis</brief_title>
  <official_title>A Pilot Study to Evaluate the Safety and Efficacy of Radiotherapy Plus Sintilimab for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tsinghua Chang Gung Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tsinghua Chang Gung Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study is an open-label, single-center, single arm phase 1b study to evaluate the
      safety and efficacy of radiotherapy plus sintilimab for HCC with PVTT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients were divided into two groups. The first group: the single dose of radiotherapy
      was 200 cGy, once a day, the total dose was 5000 cGy. The second group: the single dose of
      radiotherapy was 300 cGy, once a day, and the total dose was 3000 cGy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 25, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>Safety and tolerability of radiotherapy plus sintilimab based on NCI CTCAE v4.03 and RTOG/EORTC criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>1 year</time_frame>
    <description>Objective response rate based on RECIST v1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Portal Vein Tumor Thrombosis</condition>
  <arm_group>
    <arm_group_label>Radiotherapy Plus Sintilimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCC Patients will be received radiotherapy and concurrent Sintilimab (PD-1 inhibitor)treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Arm 1: The single radiotherapy dose was 200cGy, once a day, and the total dose was 5000cGy.
Arm 2: the single dose of radiotherapy was 300 cGy, once a day, and the total dose was 3000 cGy.</description>
    <arm_group_label>Radiotherapy Plus Sintilimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>Sintilimab is a PD-1 inhibitor, intravenously, at a dose of 200 mg, once every 3 weeks</description>
    <arm_group_label>Radiotherapy Plus Sintilimab</arm_group_label>
    <other_name>IBI308</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to understand and willingness to sign a written informed consent document.

          2. Locally advanced hepatocellular carcinoma with identified tumor thrombosis of main
             portal vein or primary branches (left and / or right branches)

          3. Has at least 1 measurable lesion

          4. Age ≥18 years

          5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          6. Adequate organ function

          7. Child Pugh class A

          8. Life expectancy ≥12 weeks.

          9. Antiviral therapy per local standard of care for hepatitis B

         10. Woman of child bearing potential must have a negative pregnancy test

         11. Must use acceptable form of birth control while on study

        Exclusion Criteria:

          1. Has previously been performed by raditotherapy for the area to be treated.

          2. With extrahepatic metastasis

          3. History of hepatic encephalopathy or liver transplantation

          4. Untreated hepatitis infection: HBV DNA&gt;2000IU/mlor10000 copy/ml, HCV RNA&gt; 1000copy/ml,
             both HbsAg and anti-HCV body are positive

          5. Has liver tumor not amenable to radiotherapy, or has had prior upper abdominal
             radiation therapy within planned volumes

          6. Has had esophageal or gastric variceal bleeding within 3 months prior to study
             enrollment

          7. With serious systemic diseases such as heart disease and cerebrovascular disease, and
             the condition is unstable or uncontrollable

          8. Evidence of active pulmonary tuberculosis (TB)

          9. Positive test of immunodeficiency virus (HIV) or acquired immunodeficiency syndrome
             (AIDS)

         10. History of allergic reactions to related drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gong Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tsinghua Changgung Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gong Li, MD</last_name>
    <phone>0086-10-56119427</phone>
    <email>dr_gongli@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tsinghua Changgung Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>102218</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gong Li, MD</last_name>
      <email>dr_gongli@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 24, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2019</study_first_posted>
  <last_update_submitted>July 5, 2020</last_update_submitted>
  <last_update_submitted_qc>July 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

